Bharat, GSK to halve price of malaria vaccine by 2028

Drugmakers Bharat Biotech and GSK will reduce the price of their malaria vaccine, Mosquirix, to $5 per dose by 2028, more than halving its current cost. This strategic price cut, driven by process improvements and expanded production capacity, aims to significantly enhance vaccine accessibility in high-burden regions like sub-Saharan Africa, where malaria causes over 500,000 annual deaths. The move, which includes GSK's technology transfer to Bharat for full production by 2028, also reinforces commitment to global health initiatives like Gavi amidst ongoing funding challenges.

Analysis

GSK, in partnership with Bharat Biotech, has announced a strategic price reduction for its Mosquirix malaria vaccine to $5 per dose by 2028, a move representing a more than 50% cut from its current price. This decision is underpinned by a technology transfer that will see Bharat Biotech assume full production by 2028, with GSK continuing to supply the critical adjuvant component. The rationale provided cites process improvements and minimal profit margins, signaling a strategy focused on volume and accessibility rather than high-margin sales. This is particularly relevant in the context of the over 500,000 annual malaria deaths and the presence of a competing vaccine from the University of Oxford and Serum Institute of India, which is already priced lower at under $4 per dose. The announcement's timing with a Gavi funding event underscores the reliance on institutional buyers for vaccine rollout in 12 African nations. While GSK has committed to supplying up to 18 million doses through 2024 and 15 million annually from 2026-2028, the low market impact score (0.4) suggests the financial contribution to a company of GSK's scale will be limited, positioning this initiative more as a long-term ESG and emerging markets access play rather than a significant near-term earnings driver.

Key Decisions for Investors

• Investors should view this development primarily through an ESG and long-term reputational framework, as the stated 'minimal profit margins' and competitive pricing environment suggest a negligible direct impact on GSK's near-term earnings.
• Monitor the competitive dynamics with the lower-priced Oxford/Serum Institute vaccine, as this will be a key determinant of market share allocation from institutional purchasers like Gavi, directly affecting future Mosquirix volumes.
• Consider the strategic value of the technology transfer, which shifts high-volume, low-margin manufacturing to a partner while retaining GSK's role as the supplier of the high-value adjuvant, potentially creating a stable, long-term revenue stream with lower operational overhead.